106 PEPTIDES
Figure 5: Primos images at different time points of a volunteer treated with the active ingredient before and after BTA injection 0 days
14 days
effective dermo-aesthetic treatments, this study has demonstrated the significant potential of a novel active peptide to complement and enhance the effects of BTA treatments. BTA is widely recognized for its ability to reduce expression wrinkles by inhibiting acetylcholine release and preventing muscle contraction. However, its effects are temporary, with wrinkles reappearing a few months post-injection. The introduction of the active peptide addresses this limitation by significantly boosting the overall impact of BTA treatments. The clinical trial results revealed that the
combination of BTA with the novel peptide led to a substantial reduction in the visibility of wrinkles on the upper face, including the forehead, frown lines, and crow’s feet, even up to four months post-treatment. This synergistic approach not only prolonged the wrinkle- reducing effects of BTA but also improved skin roughness, resulting in a smoother skin appearance in the treated areas. Additionally, advanced computer vision
techniques confirmed that the combined treatment maintained the reduction in mean wrinkle length on the forehead and frown areas up to the fourth month. These findings underscore the efficacy of
the active peptide as an invaluable addition to BTA treatments, offering a more sustained and enhanced anti-ageing solution. This research
A ■ Placebo ■ 5% Argireline Amplified peptide solution
50 40 30 20 10 0
-10 -20
-6.9% 1 month 3 months 4 months
Figure 6: A) Variation (%) in the mean wrinkle length parameter with time for the different treatments versus 14 days (***p<0.001 versus initial time at four months). Wilcoxon or Student’s t test was used after checking the normality distributions by a Shapiro-Wilk test. B) 3D LifeViz Infinity images at different time points of a volunteer treated with the active ingredient before and after BTA injection
PERSONAL CARE October 2025
www.personalcaremagazine.com
highlights a significant innovation in dermo- aesthetic treatments, providing a pathway for longer-lasting and more effective wrinkle reduction. The incorporation of Argireline Amplified peptide into BTA regiments represents a promising advancement in the field, meeting the growing consumer demand for prolonged anti-ageing solutions.
B 0 days 14 days 1 months 1 months 3 months
4 months
References 1. Malonoe M. Attitudes towards Cosmetic Procedures – UK – 2024. Mintel. https://
clients.mintel.com/content/report/ attitudes-towards-cosmetic-procedures- uk-2024
2. Satriyasa BK. Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clin. Cosmet. Investig. Dermatol. 2019; 12: 223–228.
3. Cheng CM. Cosmetic Use of Botulinum Toxin Type A in the Elderly. Clin. Interv. Aging. 2007; 2(1), 81–83
4. Blanes-Mira C, Clemente J, Jodas G, Gill A, Fernández-Ballester G, Ponsati B et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002; Oct; 24(5):303-10
5. Blanes-Mira C, Merino JM, Valera E, Fernández-Ballester G, M Gutiérrez L, Viniegra S et al. Small peptides patterned after the N-terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosis. Neurochem. 2004; Jan;88(1):124-35
PC
6. Mestre R, García N, Patiño T, Guix M, Fuentes J, Valerio-Santiago M et al. 3D-bioengineered model of human skeletal muscle tissue with phenotypic features of aging for drug testing purposes. Biofabrication. 2021; Aug.16;13(4)
11.7%
13.3% ***
3 months
4 months
Mean wrinkle length variation vs. 14 days (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112
